ACP 01
Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCellLatest Information Update: 14 Mar 2025
At a glance
- Originator Hemostemix
- Developer Hemostemix; TheraVitae
- Class Anti-inflammatories; Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Chronic limb-threatening ischemia
- Discontinued Angina pectoris; Cardiomyopathies; Heart failure; Thromboangiitis obliterans
Most Recent Events
- 06 Mar 2025 Firefly Neuroscience and Hemostemix collaborates for the development of ACP-01 for vascular dementia
- 06 Mar 2025 Hemostemix and FireFly Neuroscience plans a phase-I trial for Vascular dementia (Intrathecal)
- 25 Nov 2024 Efficacy data from the trial in Chronic limb threatening ischemia released by Hemostemix